EXECUTIVE TEAM
Introducing the TRI Executive Team led by Professor Scott Bell, CEO of TRI.
PROFESSOR Scott BellChief Executive Officer |
Professor Bell is a leading clinician and researcher in Cystic Fibrosis (CF). He recently co-led the development of a new global blueprint for the care of people with the fatal genetic disorder. His work will help the 3500 Australians with the incurable condition to live decades longer. Professor Bell has over 250 peer reviewed publications and has received grant support in excess of $22 million over the past 10 years. He is a Senior Thoracic Physician at the Prince Charles Hospital and Editor-in Chief of the Journal of Cystic Fibrosis. Prior to his appointment as TRI CEO, Professor Bell was the Executive Director of Research at Metro North Health and the head of QIMR Berghofer’s Lung Bacteria laboratory. |
|
Associate Professor Helen BenhamExecutive Director of Translation |
Associate Professor Helen Benham is an experienced rheumatologist who divides her time between clinical practice at the PA Hospital and translational research into rheumatic diseases. She is a senior lecturer with The University of Queensland and a previous NHMRC Translating Research into Practice (TRIP) Fellow. Helen has experience in clinical trials and applying the principles of implementation science to her clinical field. Currently she is a Board Member of Metro South Hospital and Health Service, the Princess Alexandra Hospital Research Foundation and is Chair of Arthritis Queensland. She holds a Bachelor of Medicine and Surgery (Hons), Bachelor of Applied Science (Podiatry), a PhD from The University of Queensland; and is a Fellow of the Royal Australasian College of Physicians and a graduate of the Australian Institute of Company Directors. |
|
|
Kirsten Kiel-ChisholmGeneral Counsel and Company Secretary |
Kirsten commenced at TRI in July 2009 and is an experienced General Counsel and Company Secretary. As Director of Legal Services, Kirsten is responsible for managing the Institute’s legal requirements and providing legal advice to the Board and management across a range of areas. She also oversees human resources and compliance for the Institute. |
Simon PrestonDirector - Finance |
Simon is a chartered accountant with more than 20 years’ experience across multiple sectors. He started his career working in external audit, including five years with the major international accounting and auditing firm, Ernst & Young. Simon then moved into commerce, taking on the role of Head of Group Finance at Virgin Care, one of the largest private providers to the UK’s National Health Service. In 2016, he joined global contract recruitment specialists Fircroft Group as Director of Group Finance. Simon relocated to Brisbane in 2019 to take up the role of Finance Director of Fircroft’s Australasian operations, before returning to professional services in 2020 as a Financial Management Consultant with BDO. During his time at BDO, Simon served as TRI’s Acting Director of Finance on two occasions, before joining TRI permanently in this role in January 2023. Simon holds a Bachelor of Economics and Finance and is a member of the Chartered Accountants Australia and New Zealand, and the Institute of Chartered Accounts in England and Wales. |
|
Melissa WatterDirector – Corporate Affairs and Marketing |
Melissa Watter joined TRI in April 2023 as Director of Corporate Affairs after two decades as co-Founder and Director of a strategic marketing and communications firm. |
|
Raj DavioDirector - ICT |
Raj initially joined TRI in 2021 in a consulting capacity with responsibility for reviewing the Institute’s ICT systems and developing a new technology strategy and governance model. In November 2022, he was formally appointed TRI's inaugural Director of ICT, with responsibility for strategic leadership of technology across the Institute. Prior to joining TRI, Raj consulted for TAFE Queensland as the Executive Director of Strategic Transformation, and before that he was the Director of IT Services at Bond University. Raj is currently on the board of a not-for-profit organisation. He holds a Bachelor of Science in Computing Science and a Master of Business in IT Management. |
|
EMILY DUGGANDirector - Service Delivery & Quality |
An accomplished biomedical research professional with over 20 years’ experience, Emily Duggan has a track record of developing innovative solutions. She joined TRI in 2022 after almost six years in the building as the University of Queensland’s Senior Gnotobiotic Facility Coordinator. In that time, she established the TRI Gnotobiotic Core Facility and her experience since has ranged from the laboratory bench through to senior management, logistics, advanced administration tasks and data analysis. Emily holds a Bachelor of Science (Hons - Class I) Physiology and Pharmacology and oversees TRI’s Core Facilities, Analytics, Scientific Services & Space, Building Services, Central Stores and Sterilisation. |
|
ROD YEODirector - People, Safety & Culture |
An experienced human resources business partner Rod Yeo has worked in a variety of sectors including Health, FMCG, Insurance, Financial Services, Mining Services and Technology. He also has a proven track record leading on Occupational Health and Safety, Quality Assurance and Change Management projects. Results driven and passionate about the importance of People, Safety and Culture in contributing to business performance, Rod holds a Master of Human Resources Management. Since joining TRI in 2017, Rod has developed a raft of HR initiatives to improve productivity, employee engagement, employee retention and leadership capability. |
|
DAVID CROWLEYGeneral Manager - Translational Biomedical Manufacturing |
David Crowley (MSc (Dist.) Biochemical Engineering) joined TRI in April 2024 following a stint as General Manager Scientific Operations & Q-Gen Cell Therapeutics at QIMR Berghofer. There David was responsible for leading and delivering strategic and operational planning for the nine bespoke facilities that make up QIMR’s Scientific Operations and their Q-Gen Cell Therapeutics cGMP manufacturing facility. He will play a pivotal role in establishing operations for our new Translational Manufacturing facility TM@TRI, due to open in late 2025. |